ES2125870T3 - Profarmacos del sertindol. - Google Patents

Profarmacos del sertindol.

Info

Publication number
ES2125870T3
ES2125870T3 ES91919394T ES91919394T ES2125870T3 ES 2125870 T3 ES2125870 T3 ES 2125870T3 ES 91919394 T ES91919394 T ES 91919394T ES 91919394 T ES91919394 T ES 91919394T ES 2125870 T3 ES2125870 T3 ES 2125870T3
Authority
ES
Spain
Prior art keywords
sertindole
group
iii
optionally substituted
nr2r3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91919394T
Other languages
English (en)
Inventor
Jens Kristian Perregaard
Henrik Perdersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Application granted granted Critical
Publication of ES2125870T3 publication Critical patent/ES2125870T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

PRODUCTOS DE REACCION DE SERTOINDOLO CON UN ACIDO O UN ACIDO ACTIVADO, SOLO CON FORMALDEHIDO, FORMALDEHIDO EN PRESENCIA DE UN ALCOHOL O UNA AMINA, O CON UN HALURO DE ACILOOXIMETILENO, Y QUE TIENE FORMULA (1) GENERAL, EN DONDE X ES CO, CS, O CH2, Y SI X ES CO O CS, R ES (I) HIDROGENO, ALQUILO, ALQUENILO, CICLOALQUILO, CICLOALQUENILO O CICLOALQU(EN)ILOALQU(EN)ILO OPCIONALMENTE SUSTITUIDO CON HIDROXILO, U OPCIONALMENTE FENILO SUSTITUIDO; O (II) YR1, EN DONDE Y ES O O S Y R1 ES UNO DE LOS SUSTITUYENTES DEFINIDOS POR R BAJO (I) ANTERIORMENTE; O (III) NR2R3, EN DONDE R2 Y R3 SE SELECCIONAN INDEPENDIENTEMENTE A PARTIR DE SUSTITUYENTES DEFINIDOS POR R BAJO (I) ANTERIOR O R2 Y R3 ESTAN COMBINADOS PARA FORMAR UN ANILLO HETEROCICLICO; O SI X ES CH2, R ES: (IV) UN GRUPO YR1 COMO SE HA DEFINIDO EN (II); (V) UN GRUPO NR2R3 COMO SE HA DEFINIDO EN (III); O (VI) UN GRUPO OC(O)R4, EN DONDE R4 ES COMO SE HA DEFINIDO PARA R1; SON PRODROGAS DE SERTOINDOLO Y MUESTRAN LIBERACION MANTENIDA DE SERTOINDOLO CUANDO SEINYECTAN COMO SE HA FORMULADO EN UN ACEITE ADECUADO. LOS COMPUESTOS SE USAN EN EL TRATAMIENTO DE DESORDENES MENTALES TALES COMO ESQUIZOFRENIA QUE INCLUYEN TANTO SINTOMAS NEGATIVOS COMO POSITIVOS, PSICOSIS DISTINTAS DE LA ESQUIZOFRENIA, DEPRESION Y ANSIEDAD.
ES91919394T 1990-10-03 1991-09-27 Profarmacos del sertindol. Expired - Lifetime ES2125870T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK238190A DK238190D0 (da) 1990-10-03 1990-10-03 Depotderivater

Publications (1)

Publication Number Publication Date
ES2125870T3 true ES2125870T3 (es) 1999-03-16

Family

ID=8111993

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91919394T Expired - Lifetime ES2125870T3 (es) 1990-10-03 1991-09-27 Profarmacos del sertindol.

Country Status (21)

Country Link
US (1) US5428036A (es)
EP (1) EP0592433B1 (es)
JP (1) JP3100980B2 (es)
KR (1) KR100212430B1 (es)
AT (1) ATE175964T1 (es)
AU (1) AU652783B2 (es)
CA (1) CA2093433C (es)
DE (1) DE69130803T2 (es)
DK (2) DK238190D0 (es)
ES (1) ES2125870T3 (es)
FI (1) FI102679B1 (es)
GR (1) GR3029399T3 (es)
HK (1) HK1009273A1 (es)
IE (1) IE913384A1 (es)
IL (1) IL99652A (es)
NO (1) NO301475B1 (es)
NZ (1) NZ240051A (es)
PH (1) PH30129A (es)
PT (1) PT99142B (es)
WO (1) WO1992006089A1 (es)
ZA (1) ZA917881B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK206591D0 (da) * 1991-12-23 1991-12-23 Lundbeck & Co As H Behandling af psykoser
JPH0625964U (ja) * 1992-05-25 1994-04-08 ミクロン機器株式会社 通信機能付きコインカウンタ及び有料装置
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
ES2387562T3 (es) 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
EP1427407A4 (en) * 2001-03-23 2005-05-11 Luitpold Pharm Inc CONJUGATES BASED ON FATTY AMINES AND PHARMACEUTICAL AGENTS
EP2129663A2 (en) * 2007-02-28 2009-12-09 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
PL2445502T5 (pl) 2009-06-25 2023-03-13 Alkermes Pharma Ireland Limited Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych
WO2010151711A1 (en) 2009-06-25 2010-12-29 Alkermes, Inc. Prodrugs of nh-acidic compounds
ES2691671T3 (es) * 2010-06-24 2018-11-28 Alkermes Pharma Ireland Limited Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato
JP7384812B2 (ja) 2018-03-05 2023-11-21 アルカームス ファーマ アイルランド リミテッド アリピプラゾール投与戦略

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3408356A (en) * 1965-08-31 1968-10-29 Squibb & Sons Inc Long chain esters of 4'-fluoro-4-[4-hydroxy-4-(alpha, alpha, alpha-trifluorotolyl)piperi-dino]butyrophenone and the like
US4038305A (en) * 1972-03-20 1977-07-26 Aktieselskabet Grindstedvaerket Cyclopentenone derivatives
GB1469108A (en) * 1973-06-25 1977-03-30 Kefalas As Thiaxanthene derivative
JPS568318A (en) * 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8621892D0 (en) * 1986-09-11 1986-10-15 Lundbeck & Co As H Organic compound
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
DE3921886A1 (de) * 1989-07-04 1991-01-17 Wolfgang Mohr Vorrichtung zum schneiden von gestapeltem, blattfoermigen gut

Also Published As

Publication number Publication date
IL99652A (en) 1997-04-15
JP3100980B2 (ja) 2000-10-23
NO301475B1 (no) 1997-11-03
NO931219L (no) 1993-04-01
CA2093433A1 (en) 1992-04-04
ZA917881B (en) 1992-07-29
US5428036A (en) 1995-06-27
KR100212430B1 (ko) 1999-08-02
NZ240051A (en) 1993-05-26
PT99142B (pt) 1999-04-30
FI102679B (fi) 1999-01-29
AU8710491A (en) 1992-04-28
FI102679B1 (fi) 1999-01-29
IE913384A1 (en) 1992-04-08
HK1009273A1 (en) 1999-05-28
PH30129A (en) 1997-01-21
FI931472A0 (fi) 1993-04-01
DK238190D0 (da) 1990-10-03
DE69130803D1 (de) 1999-03-04
IL99652A0 (en) 1992-08-18
EP0592433A1 (en) 1994-04-20
CA2093433C (en) 2000-11-21
KR930702335A (ko) 1993-09-08
AU652783B2 (en) 1994-09-08
DK0592433T3 (da) 1999-09-13
NO931219D0 (no) 1993-03-31
WO1992006089A1 (en) 1992-04-16
EP0592433B1 (en) 1999-01-20
ATE175964T1 (de) 1999-02-15
PT99142A (pt) 1994-02-28
FI931472A (fi) 1993-04-01
JPH06501939A (ja) 1994-03-03
DE69130803T2 (de) 1999-08-19
GR3029399T3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
ES2125870T3 (es) Profarmacos del sertindol.
IL104305A0 (en) Piperazine derivatives,their preparation and pharmaceutical compositions containing them
ES8305356A1 (es) Un procedimiento para la produccion de un derivado de carbostirilo
ES8504706A1 (es) Un procedimiento para la preparacion de un derivado del indol.
ATE184277T1 (de) Pleuromutilin-derivate
ATE13765T1 (de) 2-(1,4-benzodioxan-2-ylalkyl)-imidazole, deren herstellung und sie enthaltende pharmazeutische mittel.
ES475588A1 (es) Procedimiento para la obtencion de derivados del acido inde-no -2,1-b- tiofen-2-oxamico
ATE70531T1 (de) Carbacyclinester, verfahren zu ihrer herstellung und ihre verwendung in der medizin.
ATE19879T1 (de) Furyloxazolylessigsaeure-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE36520T1 (de) Polyprenylverbindung, ihre herstellung und pharmazeutische verwendung.
US3112344A (en) N -cyclopropyl-n -benzyl-am
GB949732A (en) New piperidine derivatives and process for their production
HUT53638A (en) Process for producing 15-amino-substituted 20,21-dinoreburnamenie derivatives and pharmaceutical compositions containing them
TH13395A (th) อนุพันธ์ของสเทรอยด์สำหรับใช้รักษาอาการต่อมลูกหมากโตเกินไป การเตรียมและการใช้สารนั้น
TH4801EX (th) ไพริดิล อิมิเดท สำหรับกำจัดเชื้อรา
ES8200112A1 (es) Un procedimiento para la preparacion de un derivado del aci do clavulanico.
AR003109A1 (es) Compuesto con actividad antitumoral importante y toxicidad baja y sal farmaceuticamente aceptable compuesto y composicion farmaceutica que locontiene

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 592433

Country of ref document: ES